Drug Database
BE

bevacizumab (Abevmy / bevacizumab, Biocon / Krabeva)

✓ Approved

Mylan · VEGFA · Monoclonal Antibodies

What is bevacizumab?

bevacizumab is a monoclonal antibodies developed by Mylan. It is approved for therapeutic indications via injectable (others) or intravenous (iv).

Drug Profile

Brand NamesAbevmy, bevacizumab, Biocon, Krabeva
CompanyMylan
Drug ClassMonoclonal Antibodies, Antibody
Molecular TargetVEGFA
RouteInjectable (Others), Intravenous (IV)
StatusApproved
Sources: ClinicalTrials.gov, Mylan

Mechanism of Action

Molecular Targets

bevacizumab acts on 1 molecular target:

VEGFAvascular endothelial growth factor A (VPF, MVCD1)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

bevacizumab is developed for 9 unique indications across 2 therapeutic areas.

Therapeutic AreaConditionPhase
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Non-small cell lung cancer stage IV✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Non-small cell lung cancer metastatic✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Brain neoplasm malignant✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Breast cancer✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Fallopian tube cancer✓ Approved

+4 more indications available with a free account

Sign up free to view all indications →

Related Research Articles

PubMedOncotarget2026-10-16

WIN-MTB-2024002 - WIN International Molecular Tumor Board: A 52-year-old female with unmeasurable Stage IIIc colon cancer.

El-Deiry Wafik S WS, Hernando-Calvo Alberto A, Magidi Shai S, Bresson Catherine C et al.

Copyright: © 2026 El-Deiry et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Colorectal cancer (CRC) is a leading cause of cancer-related mortality, with a complex molecular profile that impacts tumor behavior and treatment response. This case report discusses a 52-year-old female diagnosed with Stage IIIc colon cancer, exhibiting KRAS, TP53, IDH1, and APC mutations, as well as a tumor microenvironment with high PD-L1 expression and elevated VEGFR1 and VEGFR3. Despite surgical resection and adjuvant treatment which included FOLFOX, FOLFIRI with bevacizumab and local radiation, the patient’s disease was difficult to track due to small, non-FDG-avid lymph nodes in the aortocaval region and persistent circulating tumor DNA (ctDNA). Following a review by an international Molecular Tumor Board (MTB), maintenance therapy options were discussed, including the personalized combinations of regorafenib, sulindac, and metformin, or fruquintinib, sulindac, and metformin, based on the patient’s molecular alterations. Alternatively, 5-FU with or without bevacizumab was suggested. In the event of relapse, the MTB recommended the combination of regorafenib, sulindac, and metformin, with the addition of trametinib and ivosidenib. The combination of regorafenib, ipilimumab, and nivolumab (RIN) was also considered due to the patient’s high PD-L1 expression. Further clinical trial options, such as pan-RAF inhibitors, NK cell agonists, and TAS-102 with bevacizumab, were also discussed. Additionally, the potential combination of PD-1 and TGFβ inhibitors was explored. This case underscores the critical role of molecular profiling in tailoring personalized treatment strategies for advanced CRC, providing novel avenues for managing recurrent disease, even in the absence of measurable disease.

PMID 42885719
Read full article →
PubMedInternational journal of molecular sciences2026-10-16

Advances in Treatment of Refractory Advanced and Recurrent Cervical Adenocarcinoma: Molecular Heterogeneity and Differences from Squamous Cell Carcinoma.

Taira Yusuke Y, Kudaka Wataru W, Shimoji Yuko Y, Nakamoto Tomoko T et al.

Treatment for locally advanced and recurrent cervical cancer has advanced substantially with immune checkpoint inhibitors, induction chemotherapy, bevacizumab, and antibody-drug conjugates. However, subgroup analyses of major phase III trials suggest that cervical adenocarcinoma (AC) may respond differently from squamous cell carcinoma (SCC). Therefore, novel treatment strategies based on the distinct biological characteristics of AC are needed. This review aimed to evaluate the efficacy of current treatments for AC by examining histology-specific subgroup analyses from major clinical trials and to identify potential therapeutic strategies for AC. We also reviewed ongoing AC-focused clinical trials of novel molecularly targeted agents and combination therapies for advanced or recurrent disease. A structured search of PubMed and ClinicalTrials.gov through 1 June 2026, identified studies of advanced or recurrent cervical adenocarcinoma. Randomized trials, prospective studies, and histology-specific subgroup analyses were included, while case reports, preclinical studies, and SCC-only studies were excluded. Survival and response outcomes were extracted, with histology-specific findings considered exploratory. AC exhibits distinct molecular and immunological features compared with SCC, including frequent alterations in ERBB2/3, KRAS, PIK3CA, PTEN, ARID1A, and STK11 and a relatively immune-cold tumor microenvironment. HPV-independent AC, particularly gastric-type adenocarcinoma, shows aggressive clinical behavior and resistance to conventional therapies. Although bevacizumab, immune checkpoint inhibitors, and tisotumab vedotin have improved outcomes in cervical cancer, evidence specific to AC remains limited because most pivotal trials predominantly enrolled SCC or reported combined AC/adenosquamous subgroups. Emerging strategies targeting HER2, CLDN18.2, TROP2, Nectin-4, FAK, PI3K/AKT/mTOR, and ROS1 may provide new therapeutic opportunities for AC. AC represents a biologically heterogeneous disease distinct from SCC, supporting treatment strategies based on histology and molecular characteristics. Future AC-specific clinical trials and molecular stratification according to HPV association, histological subtype, and actionable alterations are needed to establish biomarker-driven personalized therapy, particularly for treatment-resistant HPV-independent AC.

PMID 42883892
Read full article →
PubMedCurrent oncology reports2026-10-16

Clinically Significant Portal Hypertension in Hepatocellular Carcinoma: Non-Invasive Assessment Across the Continuum.

Ji Pengcheng P, Luo Wenjun W, Cheng Lulu L, Xu Zhengguo Z

Clinically significant portal hypertension (CSPH) is a key determinant of surgical candidacy, locoregional therapy safety, and systemic treatment outcomes in hepatocellular carcinoma (HCC), yet its non-invasive assessment remains challenging because the Baveno criteria were derived in HCC-free cirrhosis. This review synthesises current evidence on non-invasive tests (NITs) for CSPH across the HCC care continuum, organised around three clinical scenarios: pre-operative assessment, on-treatment monitoring, and pre-immunotherapy evaluation. Liver stiffness-based Baveno rule-out retains value in early HCC but can miss haemodynamically confirmed CSPH in up to 23% of patients with favourable criteria. Spleen stiffness and imaging surrogates offer higher specificity, and longitudinal NIT monitoring is emerging as a need during locoregional and systemic therapy, which themselves can modify portal pressure. Real-world data report variceal bleeding in about 7% of patients receiving atezolizumab-bevacizumab, supporting variceal screening before anti-angiogenic treatment. AI-based multimodal models show promise in cirrhosis but lack HCC-specific validation. A scenario-based NIT strategy integrating liver stiffness, spleen stiffness, imaging collaterals, and selective HVPG measurement can guide CSPH assessment from surgical candidacy through systemic treatment. HCC-specific thresholds, longitudinal validation, and randomised evaluation of NSBB prophylaxis during immunotherapy are the highest-priority research areas.

PMID 42881321
Read full article →
PubMedCancers2026-10-16

Adjuvant and Perioperative Systemic Therapy for Resectable Hepatocellular Carcinoma: Evidence, Biological Rationale, and Trial Design.

Xin Xin X, Miao Ruoyu R

Recurrence after curative-intent resection or ablation remains a major barrier to cure in hepatocellular carcinoma (HCC). Postoperative sorafenib was neutral in STORM, the initial recurrence-free survival signal with atezolizumab plus bevacizumab in IMbrave050 was not sustained with longer follow-up, and pembrolizumab was neutral in KEYNOTE-937. By contrast, perioperative camrelizumab plus rivoceranib improved event-free survival in CARES-009. This focused narrative review separates direct HCC clinical evidence from preclinical, cross-tumor, and translational evidence and addresses three development questions: how to test the intact-tumor antigen-source hypothesis, how to select patients biologically, and how to advance perioperative regimens without compromising curative surgery. The primary tumor and its draining lymphatic network may support antigen presentation and expansion of tumor-reactive lymphocytes during checkpoint blockade, but no randomized HCC trial has isolated treatment timing while holding regimen, exposure, population, and time origin constant. CARES-009 therefore validates one complete perioperative strategy rather than proving that neoadjuvant exposure caused benefit. Biological selection should proceed across the treatment pathway: pretreatment clinical risk and liver reserve establish eligibility; on-treatment safety and tissue response assess pharmacodynamic activity; and postoperative pathology, circulating tumor DNA, alpha-fetoprotein/des-gamma-carboxy prothrombin kinetics, and spatial immune features refine residual risk. These markers are prognostic, but none has demonstrated treatment-predictive utility in a randomized biomarker-guided trial. A stage-gated development program should establish agent-specific dose and washout, preserve operability, separate timing and treatment components in randomized phase II studies, and then confirm durable event-free and overall survival in globally representative phase III trials. Durable cure without loss of surgical opportunity, hepatic reserve, or quality of life should define success.

PMID 42882822
Read full article →
PubMedCase reports in oncology2026-10-15

Long-Term Continuation Therapy with Nab-Paclitaxel and Bevacizumab ± Anti-PD-1 in Advanced Non-Small Cell Lung Cancer: Case Reports and Mechanistic Insights.

Pan Xiaofen X, Li Xueying X, Liao Jiehao J, Chen Suhua S et al.

The role of nab-paclitaxel in non-small cell lung cancer (NSCLC) as long-term continuation therapy remains underexplored, particularly in combination with anti-angiogenic agents and immunotherapy. We present 2 cases of advanced NSCLC achieving prolonged progression-free survival with nab-paclitaxel-based regimens. Case 1 (ALK-positive) received nab-paclitaxel + bevacizumab every 4 weeks for more than 48 months. Case 2 (driver-negative) received nab-paclitaxel + bevacizumab + toripalimab every 6-8 weeks for 24 months. Both patients maintained partial regression of disease, minimal toxicity (no grade, ≥3 adverse events), and preserved quality of life. The literature review highlights synergistic mechanisms of chemotherapy, anti-angiogenesis, and immunotherapy, supported by trials such as IMpower150 and KEYNOTE-407. Low-dose, extended-interval nab-paclitaxel combined with anti-angiogenesis and immunotherapy may offer a feasible maintenance strategy, warranting validation in prospective trials.

PMID 42877861
Read full article →
PubMedFrontiers in endocrinology2026-10-15

Efficacy and safety of bevacizumab plus XELOX in patients with unresectable locally advanced or metastatic neuroendocrine tumors.

Wang Huike H, Tan Huijing H, Sun Yuting Y, Su Yanwei Y et al.

Neuroendocrine tumors (NETs) are highly vascularized malignancies for which effective treatment options remain limited in the unresectable locally advanced or metastatic setting. Although platinum-based chemotherapy has demonstrated antitumor activity in advanced NETs, evidence supporting its combination with antiangiogenic therapy remains insufficient. In this retrospective study, 85 patients with progressive unresectable locally advanced or metastatic well-differentiated NETs initiated bevacizumab plus XELOX, consisting of bevacizumab at 7.5 mg/kg and oxaliplatin at 130 mg/m² every 3 weeks, together with capecitabine at 1,000 mg/m² twice daily on days 1-14 of each 21-day cycle. Among them, 72 patients who completed at least two treatment cycles and underwent post-baseline radiological evaluations comprised the safety set. The primary endpoint was objective response rate (ORR) by RECIST v1.1, while secondary endpoints included disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and safety. Among the efficacy-evaluable patients, 62 (86.1%) received the regimen as second-line or later systemic therapy. Best responses included complete response (CR) in 1 patient (1.4%), partial response (PR) in 29 (40.3%), stable disease (SD) in 41 (56.9%), and progressive disease (PD) in 1 (1.4%), resulting in an ORR of 41.7% and a DCR of 98.6%. In a conservative sensitivity analysis encompassing all 85 treated patients-treating the 13 non-evaluable patients as non-responders-the ORR was 35.3%. After a median follow-up of 17.2 months, the median PFS was 20.9 months (95% CI, 13.7 months-not reached), with 6-, 12-, and 24-month PFS rates of 84.7%, 69.6%, and 47.3%, respectively. Median OS was not reached, and OS data remained immature. The most frequent any-grade adverse events (AEs) were elevated aspartate aminotransferase (48.6%), anemia (44.4%), lymphopenia and hypoalbuminemia (41.7% each), and hyperglycemia (40.3%), while neutropenia was the most frequent individual grade ≥3 AE (5.6%). No grade ≥3 bevacizumab-specific toxicities were observed. These findings suggest that bevacizumab plus XELOX demonstrates clinically meaningful antitumor activity and a manageable safety profile in advanced NET patients. Given the retrospective and single-arm design, this regimen may represent a potential alternative or sequential treatment option when alkylating-agent-based chemotherapy is unsuitable, whereas prospective comparative studies are warranted to validate these findings and determine its optimal clinical role.

PMID 42876479
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about bevacizumab